临床应用二氢吡啶类钙通道阻滞剂的循证医学评价

被引：6

作者：

鲁风云 ^{[1
,2
]}

段京莉 ^{[1
]}

机构：

[1] 北京大学第三医院药剂科

[2] 北京大学药学院

来源：

中国医院用药评价与分析 | 2009年 / 9卷 / 02期

关键词：

二氢吡啶类钙通道阻滞剂; 循证医学; 系统评价;

D O I：

10.14009/j.issn.1672-2124.2009.02.016

中图分类号：

R96 [药理学];

学科分类号：

100602 ; 100706 ;

摘要：

目的:评价二氢吡啶类钙通道阻滞剂(DHP-CCB)的临床应用进展,及其有效性和安全性。方法:搜集DHP-CCB临床应用相关的系统评价及大规模临床对照研究,对DHP-CCB和安慰剂或者其它药物进行比较,评价其有效性和安全性。结果:共检索到3项大型临床研究和20项系统评价,对DHP-CCB应用于高血压、心绞痛、蛛网膜下腔出血、抑制分娩等症状的有效性和安全性进行评价。结论:DHP-CCB在控制收缩压和舒张压上和其它药物效果相同,与其它降压药合用,效果和安全性更好。在老年单纯收缩期高血压患者,应用DHP-CCB明显降低肾功能不全和痴呆。DHP-CCB与β-受体阻滞剂合用于冠心病患者中,效果和安全性更好。DHP-CCB能够改善蛛网膜下腔出血预后。在抑制分娩中,DHP-CCB较其它抑制分娩药更有效,安全性更好。DHP-CCB应用于缺血性卒中的安全性和有效性尚待进一步的临床数据证实。

引用

页码：84 / 87

页数：4

共 12 条

[1]

Carotid Intima-Media Thickness and Antihypertensive Treatment: A Meta-Analysis of Randomized Controlled Trials[J] . Ji-Guang Wang,Jan A. Staessen,Yan Li,Luc M. Van Bortel,Tim Nawrot,Robert Fagard,Franz H. Messerli,Michel Safar.Stroke . 2006 (7)

[2]

Effect of nimodipine on outcome in patients with traumatic subarachnoid haemorrhage: a systematic review[J] . Mervyn DI Vergouwen,Marinus Vermeulen,Yvo BWEM Roos.Lancet Neurology . 2006 (12)

[3]

Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: a meta-analysis with an indirect comparison of randomised trials[J] . Aravinthan Coomarasamy,Ellen M Knox,Harry Gee,Fujian Song,Khalid S Khan.BJOG: An International Journal of Obstetrics and Gynaecology . 2003 (12)

[4]

Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis[J] . Werner W. Klein,Graham Jackson,Luigi Tavazzi.Coronary Artery Disease . 2002 (8)

[5]

Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials[J] . Marco Pahor,Bruce M Psaty,Michael H Alderman,William B Applegate,Jeff D Williamson,Chiara Cavazzini,Curt D Furberg.The Lancet . 2000 (9246)

[6]

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment （INSIGHT）[J] . Morris J Brown,Christopher R Palmer,Alain Castaigne,Peter W de Leeuw,Giuseppe Mancia,Talma Rosenthal,Luis M Ruilope.The Lancet . 2000 (9227)

[7]

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials[J] . The Lancet . 2000 (9246)

[8]

Safety of Nifedipine in Angina Pectoris: A Meta-Analysis[J] . William B. Stason,Christopher H. Schmid,Donna Niedzwiecki,Gregory W. Whiting,Jean-Francois Caubet,Douglas Cory,Don Luo,Susan D. Ross,Thomas C. Chalmers.Hypertension . 1999 (1)

[9]

Safety of Nifedipine in Patients With Hypertension: A Meta-Analysis[J] . William B. Stason,Christopher H. Schmid,Donna Niedzwiecki,Gregory W. Whiting,Donghan Luo,Susan D. Ross,Thomas C. Chalmers.Hypertension . 1997 (1)

[10]

Nimodipine in traumatic subarachnoid haemorrhage: A re-analysis of the HIT I and HIT II trials[J] . G. D. Murray,G. M. Teasdale,H. Schmilz.Acta Neurochirurgica . 1996 (10)

← 1 2 →